Press Release Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan ‚¬3 million upfront payment and a total of a further potential ‚¬27.5 million in...
MONTGOMERY, Ala.--(BUSINESS WIRE)--Kowa Pharmaceuticals America, Inc. announced the publication of Phase 3 clinical trial results in Pain Practice reinforcing that SEGLENTIS® a unique co-crystal combination of celecoxib 56-mg and tramadol hydrochloride 44-mg, and oral treatment for appropriate patients with acute pain, provided superior analgesic efficacy than tramadol hydrochloride or celecoxib individually, and a safety profile similar to tramadol hydrochloride, while meeting its primary endpoint. As a multimodal agent, SEGLENTIS leverages 4 complimentary mechanisms of analgesia involving peripheral and central pathways.